UCB de­tails pos­i­tive piv­otal da­ta for myas­the­nia gravis, days af­ter As­traZeneca scores OK for Soliris suc­ces­sor

4 years ago
Pharma

ICER: Mer­ck­'s Covid-19 pill does­n't show 'net health ben­e­fit' but price is rea­son­able

4 years ago
Pharma
Coronavirus

Pro­tein degra­da­tion field turns red hot as Bris­tol My­ers signs up for an­oth­er multi­bil­lion-dol­lar pact

4 years ago
Deals

Mar­ket­ingRx roundup: GSK de­buts Voltaren se­ries with celeb; Ab­b­Vie bows new Mavyret hep C TV ad

4 years ago
Pharma
Marketing

No­vo Nordisk gets se­ri­ous in ‘Get Re­al’ di­a­betes cam­paign with spokesman, ac­tor and pa­tient An­tho­ny An­der­son

4 years ago
Pharma
Marketing

Up­dat­ed: A GPCR start­up out of France and Cana­da scores its Se­ries A af­ter 14 years of wheel­ing and deal­ing

4 years ago
Financing

Cap­ping a tur­bu­lent saga around Alzheimer's drug, Cor­texyme strikes a deal, brings in new man­age­ment and changes name ...

4 years ago
Deals

Verve gets New Zealand clear­ance to test base edit­ing ther­a­py di­rect­ly in the hu­man body

4 years ago
R&D
Cell/Gene Tx

'Front and cen­ter': In­dus­try lead­ers call for re­sponse to Supreme Court abor­tion case draft

4 years ago
People

Fi­bro­Gen CEO: Roxa path blocked as As­traZeneca re­mains un­de­cid­ed on just what it plans to do in the wake of a CRL

4 years ago
R&D
Pharma

As Sanofi prunes pipeline, ex-Alex­ion crew at Rally­bio picks up ane­mia drug

4 years ago
Deals
Pharma

Af­ter rack­ing up 41 Covid jab nods out­side US, No­vavax hits first prof­itable quar­ter but still dis­ap­points in­vestors

4 years ago
Pharma
Coronavirus

Bio­gen piv­ots to sec­ond amy­loid-tar­get­ed Alzheimer's drug with ac­cel­er­at­ed ap­proval fil­ing from part­ner Ei­sai

4 years ago
R&D
FDA+

Can On­co­Host's PROphet pre­dict host re­sponse to can­cer treat­ments? In­vestors are wait­ing to find out

4 years ago
Financing
Diagnostics

As biotech mar­ket re­mains chilly, Longeveron CEO steps down af­ter 18-month run

4 years ago
People

Till­man Gern­gross pass­es the Adimab ba­ton af­ter 15 years, mov­ing from CEO to ex­ec­u­tive chair­man role

4 years ago
People

Pfiz­er buys Bio­haven for $11.6B, go­ing all in on CGRP mi­graine drug port­fo­lio

4 years ago
Deals

Work­ing like a ma­chine dur­ing the pan­dem­ic, MO­MA taps in­vestors to bankroll its 'mol­e­c­u­lar ma­chi­nes'

4 years ago
Financing
Startups

An­oth­er TIG­IT up­date from Ar­cus leaves an­a­lysts read­ing the tea leaves — and the big re­veal is fi­nal­ly near

4 years ago
R&D

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at ...

4 years ago
Deals
R&D

Seagen CEO Clay Sie­gall was placed on leave af­ter an April 23 ar­rest for do­mes­tic vi­o­lence gross mis­de­meanor

4 years ago
People
Pharma

Wrong par­ty, wrong court: Mod­er­na fights back against patent in­fringe­ment case sur­round­ing its Covid-19 vac­cine

4 years ago
Pharma
Law

Home­grown mR­NA Thai vac­cine for Covid-19 could be ready by year end — re­port

4 years ago
Pharma
Manufacturing

Deep­In­tent ponies up ad guar­an­tees to take the edge off phar­mas' pro­gram­mat­ic ad hes­i­ta­tion

4 years ago
Pharma
Marketing
First page Previous page 523524525526527528529 Next page Last page
A service from the Financial Times